Moon J, et al. – Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Authors performed this study assessing the efficacy and safety of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease. In this study, the fixed–dose combination ledipasvir and sofosbuvir for 12 weeks proved safe and efficacious in this population.